These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8640913)

  • 1. Association of low CYP3A activity with p53 mutation and CYP2D6 activity with Rb mutation in human bladder cancer.
    Romkes M; Chern HD; Lesnick TG; Becich MJ; Persad R; Smith P; Branch RA
    Carcinogenesis; 1996 May; 17(5):1057-62. PubMed ID: 8640913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors.
    Branch RA; Chern HD; Adedoyin A; Romkes-Sparks M; Lesnick TG; Persad R; Wilkinson GR; Fleming CM; Dickinson AJ; Sibley G
    Pharmacogenetics; 1995; 5 Spec No():S97-102. PubMed ID: 7581498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.
    Kaisary A; Smith P; Jaczq E; McAllister CB; Wilkinson GR; Ray WA; Branch RA
    Cancer Res; 1987 Oct; 47(20):5488-93. PubMed ID: 3652049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
    Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
    Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochromes in psychopharmacology.
    von Moltke LL; Greenblatt DJ; Harmatz JS; Shader RI
    J Clin Psychopharmacol; 1994 Feb; 14(1):1-4. PubMed ID: 8150999
    [No Abstract]   [Full Text] [Related]  

  • 6. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients.
    Eap CB; Bender S; Gastpar M; Fischer W; Haarmann C; Powell K; Jonzier-Perey M; Cochard N; Baumann P
    Ther Drug Monit; 2000 Apr; 22(2):209-14. PubMed ID: 10774635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer.
    Fleming CM; Kaisary A; Wilkinson GR; Smith P; Branch RA
    Pharmacogenetics; 1992 Jun; 2(3):128-34. PubMed ID: 1306112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes.
    Masimirembwa CM; Gustafsson LL; Dahl ML; Abdi YA; Hasler JA
    Br J Clin Pharmacol; 1996 Apr; 41(4):344-6. PubMed ID: 8730982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSTM1 and CYP2D6 genotype frequencies in patients with pituitary tumours: effects on P53, ras and gsp.
    Perrett CW; Clayton RN; Pistorello M; Boscaro M; Scanarini M; Bates AS; Buckley N; Jones P; Fryer AA; Gilford J
    Carcinogenesis; 1995 Jul; 16(7):1643-5. PubMed ID: 7614700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
    Bork JA; Rogers T; Wedlund PJ; de Leon J
    J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
    Masubuchi Y; Hosokawa S; Horie T; Suzuki T; Ohmori S; Kitada M; Narimatsu S
    Drug Metab Dispos; 1994; 22(6):909-15. PubMed ID: 7895609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo modulation of CYP enzymes by quinidine and rifampin.
    Branch RA; Adedoyin A; Frye RF; Wilson JW; Romkes M
    Clin Pharmacol Ther; 2000 Oct; 68(4):401-11. PubMed ID: 11061580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
    Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
    Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A).
    Yasumori T; Chen L; Nagata K; Yamazoe Y; Kato R
    J Pharmacol Exp Ther; 1993 Jan; 264(1):89-94. PubMed ID: 8423554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer.
    Brockmöller J; Kaiser R; Kerb R; Cascorbi I; Jaeger V; Roots I
    Pharmacogenetics; 1996 Dec; 6(6):535-45. PubMed ID: 9014203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.
    Botsch S; Gautier JC; Beaune P; Eichelbaum M; Kroemer HK
    Mol Pharmacol; 1993 Jan; 43(1):120-6. PubMed ID: 8423765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
    Ramírez J; Innocenti F; Schuetz EG; Flockhart DA; Relling MV; Santucci R; Ratain MJ
    Drug Metab Dispos; 2004 Sep; 32(9):930-6. PubMed ID: 15319333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The relationship between single-oral dose kinetics of alprazolam and cytochrome P4503A and cytochrome P4502C19].
    Yasui N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Jun; 16(3):109-12. PubMed ID: 8905799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
    Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
    J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.